Download Our Operating Companies Our Vision for the Future Our Expanding

Endo International plc Corporate Fact Sheet
Endo International plc is a global specialty pharmaceutical company focused on improving the lives of patients
while creating value. Endo develops, manufactures, markets and distributes quality branded and generic
pharmaceutical products as well as over-the-counter medications through our operating companies –
Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha. Endo commenced
operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from
The DuPont Merck Pharmaceutical Company. Since that time, the company has expanded to include
the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals
and International Pharmaceuticals.
Endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating
model with focused and disciplined execution that allows us to pursue growth opportunities
both organically and through selective acquisitions. Additionally, we are leveraging a research
and development model that focuses on lower risk, near-term projects. Our goal is to
consistently create value for our shareholders while serving our patients and customers.
TM
Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania.
We employ approximately 6,200 people worldwide*. For more information about Endo International
and our operating companies, please visit www.endo.com.
As of 2/19/2016
*
Our Operating Companies
Our Vision for the Future
Endo International plc
We are poised to deliver on a new vision for
Business Segments
Endo: to become a leading global specialty
U.S. Generic
Pharmaceuticals
U.S. Branded
Pharmaceuticals
International
Pharmaceuticals
pharmaceutical company that improves
lives while creating value. To accomplish
Operating Companies
Endo
Par Pharmaceutical
Paladin Labs
our vision for the benefit of patients,
High-value branded pharmaceutical
products that meet the unmet
needs of patients.
Develops, manufactures and markets
safe, innovative and cost-effective generic
products, as well as branded and generic
sterile injectable pharmaceutical products,
that help improve patient quality of life.
Providing innovative pharmaceutical
products for the Canadian market.
customers and our shareholders, we
Pharmaceuticals
SOMAR
Focused on developing,
manufacturing and marketing
high-quality generic, brandedgeneric and over-the-counter
products across key market
segments in Mexico.
Litha
Diversified healthcare group
providing services & products
to the Southern African market.
have embraced a common set of guiding
principles that enable us to provide quality
products that serve patient needs. We will
be more nimble and entrepreneurial in our
approach to the business. We will be the
best managers of our assets, continuing
to deliver relevant products to the market.
Our Expanding Global Presence
We will always act in a compliant and
ethical manner in the way we do business,
Chestnut Ridge, NY
Par Pharmaceutical Headquarters
Manufacturing and R&D Facilities
Montebello, NY & Stratford, CT
Distribution and Manufacturing Facilities
Montreal, Canada
Paladin Labs Headquarters
Rye, NY
Manufacturing Facilities
Irvine, CA
Manufacturing Facilities
Malvern, PA
Endo U.S. Headquarters
Huntsville, AL
Manufacturing Facilities
dedication and experience of our talented
Horsham, PA
Manufacturing Facilities
Charlotte, NC
Manufacturing
Facilities
ahead and outperforming our competitors.
We believe in making a difference, and the
Cranbury, NJ
Manufacturing Facilities
Rochester, MI
Manufacturing Facilities
while at the same time staying a step
people guide that aspiration. As a fast-paced
and forward-looking company, Endo is
Ireland
Endo International Global
Headquarters
United Kingdom
Par Laboratories Europe, Ltd.
Sales, R&D
continuously growing and developing – and
we encourage each employee to do the same.
Mexico City, Mexico
Grupo Farmacéutico SOMAR Headquarters &
Manufacturing Facilities
Midrand, South Africa
Litha Healthcare Group
Headquarters
Chennai, India
Par R&D, Manufacturing
and API Facilities
www.endo.com
Our Management Team
Paul V. Campanelli*
Joseph A. Barbarite
Patrick Barry
Mark Bradley
Blaise Coleman*
Terrance J. Coughlin*
Larry Cunningham
Jennifer E. Dubas Rahul Garella
Matthew Maletta* Stephen Mock Tony Pera
Brandon Rockwell
Dan Rudio*
President, Chief Executive Officer and Director
Executive Vice President, Global Quality and Compliance
Senior Vice President, U.S. Branded Pharmaceuticals
Senior Vice President, Corporate Development
Executive Vice President and Chief Financial Officer
Executive Vice President and Chief Operating Officer
Executive Vice President, Human Resources
Senior Vice President and Chief Compliance Officer
Senior Vice President, Head of International Pharmaceuticals
Executive Vice President, Chief Legal Officer
Senior Vice President, Investor Relations and Corporate Affairs
President, Par Pharmaceutical
Vice President, Business Development
Vice President, Controller and Chief Accounting Officer
Our History
*Section 16(b) Executive Officers
2014
Endo completes its divestiture
of HealthTronics to Altaris
Capital Partners, LLC
Endo acquires Boca
Pharmacal as part
of Qualitest business
Endo acquires
Paladin Labs
Endo and Paladin
come together under
Endo International plc.
Endo establishes new
global headquarters
in Dublin, Ireland
2010
Endo acquires HealthTronics,
Penwest Pharmaceuticals and
Qualitest Pharmaceuticals
Endo acquires
Grupo Farmacéutico SOMAR
The U.S. FDA approves
FORTESTA® Gel for the treatment
of low testosterone, or ‘Low T,’
also known as hypogonadism
1994
DuPont Merck establishes
Endo as its generics entity
1920
Intravenous Products of
America, Inc. is founded as
family run pharmaceutical
company in New York City
2000
Endo Pharmaceuticals
Holdings Inc. begins to trade
publicly on NASDAQ (ENDP)
1997
DuPont executives form
Endo Pharmaceuticals Inc. in
management buyout, obtaining
a broad portfolio of generic
and branded products
2006
Endo receives FDA approval
for OPANA® and OPANA® ER,
which represents the first
internally developed NDAs
to be granted FDA approval
2009
Endo acquires Indevus to
diversify pharmaceutical
portfolio into urology
2012
Endo announces the
aggregation of its operating
companies as part of an
enterprise-wide branding
initiative and changes the
parent company name to
Endo Health Solutions Inc.
2011
Endo acquires American
Medical Systems (AMS)
Endo acquires DAVA
Pharmaceuticals as part
of Qualitest business
The U.S. FDA approves
AVEED® (Testosterone
Undecanoate) injectable
testosterone replacement
therapy for men living with
hypogonadism, or Low T
2013
Endo announces strategic
change to focus on
providing quality products
through its operating
companies, and announces
restructuring to improve
operating margin and
operational effectiveness
2016
Endo winds down ASTORA
Women’s Health Business
(formerly AMS Women’s Health)
2015
Endo acquires Auxilium
Pharmaceuticals, Inc. as
part of Endo Pharmaceuticals
business
Endo completes acquisition
of Litha Healthcare Group
Endo completes its divestiture of
AMS Men’s and Prostate Health
Businesses to Boston Scientific
Endo completes acquisition
of specialty generics and
sterile injectables company
Par Pharmaceutical Holdings Inc.
Par is combined with Qualitest
to create expanded U.S.
Generics business named
Par Pharmaceutical
Endo announces that the U.S.
FDA approves BELBUCA™
(buprenorphine) buccal film for use
in patients with chronic pain severe
enough to require daily, around-theclock, long-term opioid treatment
and for which alternative treatment
options are inadequate
Our Corporate Information
Endo Global Headquarters
First Floor, Minerva House
Simmonscourt Road
Ballsbridge
Dublin 4
Ireland
+353 1 268 2000
Endo U.S. Headquarters
1400 Atwater Drive
Malvern, PA 19355
484-216-0000
(800) 462-ENDO (3636)
Investors/Media and Government Affairs
Stephen Mock
Senior Vice President, Investor Relations
and Corporate Affairs
845-364-4833
[email protected]
Investors
Nina Goworek
Senior Director, Investor Relations
484-216-6657
[email protected]
Media
Heather Zoumas-Lubeski
Senior Director, Corporate Affairs
484-216-6829
[email protected]
NASDAQ/TSX Ticker Symbol: ENDP
Revised: December 2016
© 2016 Endo Pharmaceuticals Inc. www.endo.com